In The News Posted November 12, 2020 Share Posted November 12, 2020 JERUSALEM, Nov. 12, 2020 /PRNewswire/ -- KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced dosing of the first patient in its Phase 1/2 clinical trial (NCT04440735) assessing its lead product, DSP107, a bi-functional...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.